NCT06216197View on ClinicalTrials.gov

Dexmedetomidine Versus Fentanyl as an Adjuvant to Bupivacaine in Saddle Block

NACompletedINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

April 3, 2021

Primary Completion Date

December 4, 2022

Study Completion Date

December 4, 2022

Conditions
Regional Anesthesia Morbidity
Interventions
DRUG

FENT group

Group FENT, consisting of 29 patients, underwent a saddle block with hyperbaric bupivacaine (2.5 ml) combined with fentanyl (0.5 ml; 25 μg).

DRUG

DEX group

The DEX Group, consisting of 29 patients, received 2.5 ml of hyperbaric bupivacaine mixed with dexmedetomidine (10 μg; 0.5 ml).

Trial Locations (1)

12546

Al-Azhar faculty of medicine, Cairo

All Listed Sponsors
lead

Zulekha Hospitals

OTHER

NCT06216197 - Dexmedetomidine Versus Fentanyl as an Adjuvant to Bupivacaine in Saddle Block | Biotech Hunter | Biotech Hunter